C
카나프테라퓨틱스
0082N0KOSDAQ자연과학 및 공학 연구개발업46.5 / 100
Reference Date: 2026-04-13
Financial Score20.0 / 40
News Sentiment12.5 / 25
Momentum4.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is low with sound financial health. Plunged 26.3% over the past month, and news sentiment is neutral.
Company InformationBased on 2025 Annual Report
Business Overview
Canapharmaceuticals is an innovative biopharmaceutical company developing novel drugs for oncology and ophthalmic diseases using human genome-based technology. The company has a diverse pipeline of seven projects, including bispecific antibodies, ADCs, and synthetic drugs, and has secured significant revenue through early-stage technology transfers and co-development partnerships with major pharmaceutical firms in South Korea.
Number of Employees
23people
Average Salary
55.1M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 120.074.0Point
PBR
—Industry Average 3.823.5Point
ROE
—Industry Average -32.113.5Point
Debt Ratio
5.73Industry Average 7.524.0Point
In line with industry avg
Trend 5.0 / 10 points
Revenue Growth Rate
1.5 / 3
Operating Profit Growth Rate
1.5 / 3
ROE Trend
2.0 / 4
Detailed News Sentiment
1 totalPositive 0Neutral 0Negative 0
- Neutral
Detailed Momentum
52-week position3.0Point
52w lower range (21%)
Current 37,300Won52-week high 52,20052-week low 33,250
1-month return0.0Point
1m -26.28% (strong drop)
Volume trend1.0Point
Volume dry-up
Detailed Disclosure
19 totalPositive 0Neutral 19Negative 0
- Neutral정기주주총회결과2026-03-30
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-03-23
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-03-23
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-03-23
- Neutral주식등의대량보유상황보고서(약식)2026-03-23